Research Article
Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer
Table 6
Summary of top pathways returned by KEGG using DAVID for early- and late-stage cancer.
| Early-stage NSCLC | Term | Count | % | value |
| Leukocyte transendothelial migration | 4 | 18.2 | 0.00294 | Glycolysis/gluconeogenesis | 3 | 13.6 | 0.00982 | Epithelial cell signaling in Helicobacter pylori infection | 3 | 13.6 | 0.0125 | Cell adhesion molecules (CAMs) | 3 | 13.6 | 0.0432 | Tight junction | 3 | 13.6 | 0.0444 | Focal adhesion | 3 | 13.6 | 0.0911 |
| Late-stage NSCLC | Term | Count | % | value |
| Cell cycle | 12 | 19.7 | | Oocyte meiosis | 8 | 13.1 | | Progesterone-mediated oocyte maturation | 6 | 9.8 | | DNA replication | 3 | 4.9 | 0.0250 | p53 signaling pathway | 3 | 4.9 | 0.0791 |
|
|